Form 4: Aquestive Therapeutics Director Julie Krop Granted 42,000 Stock Options

Aquestive Therapeutics, Inc. Director Julie Krop was granted 42,000 stock options with an exercise price of $3.41, vesting fully on June 11, 2026.

Summary

• Julie Krop, a Director of Aquestive Therapeutics, Inc. (AQST), acquired 42,000 stock options.
• The transaction date for the option grant was June 11, 2025.
• Each option has an exercise price of $3.41.
• The options are for Common Stock of Aquestive Therapeutics, Inc.
• The shares underlying these options will vest 100% on June 11, 2026, contingent upon Dr. Krop's continuous service with the Issuer from the grant date through the vesting date.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Dr. Krop beneficially owns 42,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine equity compensation event, aligning the director's interests with long-term shareholder value, which is generally viewed as a neutral to slightly positive development for corporate governance.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Aquestive Therapeutics, Inc.
• Equity compensation is a standard practice to attract and retain qualified board members.

Future Outlook

The vesting schedule indicates that the options are intended to incentivize the director's continued service to the company through at least June 11, 2026, aligning their future efforts with the company's performance.

Industry Context

The grant of stock options to a director is a common form of equity compensation in the biotechnology and pharmaceutical industries, used to align the interests of board members with those of shareholders and to incentivize long-term commitment and performance.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages across the biotech and pharmaceutical sectors, comparable to practices at companies like BioNTech, Moderna, or Pfizer, which also utilize equity to incentivize leadership.
• The vesting schedule, requiring continuous service, is typical for such grants, ensuring retention and alignment over a specified period.

Corporate Governance

Related Party Transactions

• The grant of stock options to Julie Krop, a Director of Aquestive Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying compensation to stock performance, potentially encouraging decisions that enhance long-term value.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The stock options will vest on June 11, 2026, subject to Dr. Krop's continuous service.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Stock Option, Equity Grant, Insider Transaction, Form 4, Julie Krop, Director Compensation, Beneficial Ownership